期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 55, 期 3, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ijantimicag.2019.105865
关键词
Candida; antifungal; ADME; in vivo; in vitro; pharmacokinetics
资金
- ICMR [AMR/149/2018-ECD-II]
- DBT [BT/PR14117/BRB/10/1420/2015]
- University Grant Commission
- Italian Ministry of University and Research (Linea D1 UniversitaCattolica del Sacro Cuore)
- Cygnet Biosciences B.V., Kaya Richard J. Beaujon Z/N, Curacao
Background: Candida species are one of the most common causes of nosocomial bloodstream infections among the opportunistic fungi. Extensive use of antifungal agents, most of which were launched on the market more than 20 years ago, led to the selection of drug-resistant or even multidrug-resistant fungi. We recently described a novel class of antifungal macrocyclic compounds with an amidinourea moiety that is highly active against azole-resistant Candida strains. Objective: A compound from this family, BM1, was investigated in terms of in vitro activity against various Candida species, including C. auris isolates, interaction with the ABC transporter, CDR6, and in vivo distribution and safety. Methods: In vitro assays (CYP inhibition, microsomal stability, permeability, spot assays) were used to collect chemical and biological data; animal models (rat) paired with LC-MS analysis were utilised to evaluate in vivo toxicology, pharmacokinetics, and distribution. Results: The current research shows BM1 has a low in vivo toxicity profile, affinity for the renal system in rats, and good absorption, distribution, metabolism, and excretion (ADME). BM1 also has potent activity against azole-resistant fungal strains, including C. auris isolates and CDR6-overexpressing strains. Conclusions: The results confirmed low minimum inhibitory concentrations (MICs) against several Candida species, including preliminary data vs. C. auris. BM1 has good ADME and biochemical characteristics, is suitable and safe for daily administration and is particularly indicated for renal infections. These data indicate BM1 and its derivatives form a novel, promising antifungal class. (C) 2019 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据